In this week’s video, Dr. Brian G.M. Durie discusses the pros and cons of newer “immune therapies,” including monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and CAR-T cells.

Immune therapies are here to stay, and many will be impactful in the next few years. 

Have a question? Submit it to [email protected]

IMF Chairman and Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to [email protected]!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at [email protected]

Image of Dr. Brian G.M. DurieDr. Brian G.M. Durie serves as Chairman of the International Myeloma Foundation and serves on its Scientific Advisory Board. Additionally, he is Chairman of the IMF's International Myeloma Working Group, a consortium of nearly 200 myeloma experts from around the world. Dr. Durie also leads the IMF’s Black Swan Research Initiative®.

Previous Post
Are routine skeletal survey X-rays still recommended?
Next Post
How many times can a myeloma patient undergo an autologous stem cell transplant?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.